Report
Oscar Haffen Lamm

Cinclus: preparations on track to start phase 3 trial

Cinclus Pharma reported its Q3'24 results with a cash position at SEK644.2m and an EBIT at SEK(39.15m). On the operational side, i) all is on track to recruit the first patient for its phase 3 trial in 2025, with topline data on the healing part expected in Q2/Q3 2026, and ii) market approval of li
Underlying
CINCLUS PHARMA HOLDING AB

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Oscar Haffen Lamm

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch